Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. AbbVie Inc. (NYSE:ABBV), a biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. If You Bought AbbVie Stock 10 Years Ago The company's stock traded at approximately $64.32 per share 10 years ago. If you had invested $10,000, you could have bought roughly 155 shares. Currently, shares trade at $193.34, meaning your investment's value could have grown to $30,059 from stock price appreciation alone. However, AbbVie also paid dividends during these 10 years. Don't Miss: Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Last Chance to get 4,000 of its pre-IPO shares for just $0.30/share! Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today. AbbVie's dividend yield is currently 3.39%. Over the last 10 years, it has paid about $45.67 in dividends per share, which means you could have made $7,100 from dividends alone. Summing up $30,059 and $7,100, we end up with the final value of your investment, which is $37,159. This is how much you could have made if you had invested $10,000 in AbbVie stock 10 years ago. This means a total return of 271.59%. In comparison, S&P 500 total return for the same period is 221.50%. What Could The Next 10 Years Bring? AbbVie has a consensus rating of "Buy" and a price target of $200.03 based on the ratings of 34 analysts. The price target implies more than a 3% potential upside from the current stock price. Trending: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. On April 25, the company announced its Q1 2025 earnings, posting adjusted EPS of $2.46, up 6.5% year-over-year, and beating the consensus of $2.38, as reported by Benzinga. The pharmaceutical giant reported sales of $13.34 billion, coming in above the consensus of $12.92 billion. “AbbVie’s first-quarter results were well ahead of our expectations and reflect an excellent start to the year,” said CEO Robert Michael. “The fundamentals of our business are strong, and we continue to bolster our outlook with pipeline advancements and strategic investments. Based on the progress we are making, AbbVie is well positioned for the long term.” The company raised its full-year 2025 adjusted EPS from the range of $11.99 to $12.19 to $12.09 to $12.29, compared to the consensus of $12.17. Story Continues See Also: If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? How much would it take to earn $100 a month from AbbVie stock. Check out this article by Benzinga to learn more. Given the historical stock price appreciation and expected upside potential, growth-focused investors may find AbbVie stock attractive. Furthermore, they can benefit from the company's solid dividend yield of 3.39%. Read Next: Donald Trump Just Announced a $500 Billion AI Infrastructure Deal — Here's How You Can Invest in the Entertainment Market's Next Big Disruptor for Just $998 ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share with a $1000 minimum. Image: Shutterstock Send To MSN: 0 This article If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now? originally appeared on Benzinga.com View Comments
If You Invested $10K In AbbVie Stock 10 Years Ago, How Much Would You Have Now?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...